Product
GB1211
4 clinical trials
5 indications
Indication
pharmacokineticsIndication
Liver ImpairmentIndication
Metastatic MelanomaIndication
Head and Neck Squamous Cell CarcinomaIndication
NSCLCClinical trial
An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).Status: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
An Open-label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 Upon Dosing a Capsule Under Fasting Condition and a Tablet Under Fasting and Fed Conditions in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-04-10
Clinical trial
GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)Status: Active (not recruiting), Estimated PCD: 2022-07-18
Clinical trial
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-02-01